請輸入關鍵字:

熱門搜尋:

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

日期: 2020年2月19日 上午9:50

Boehringer Ingelheim offers MyStudyWindow to provide patients, families, caregivers, and doctors consistent access to information about Boehringer Ingelheim’s actively recruiting studies conducted at global site locations
The platform features patient-centric study titles and descriptions, educational content, and guidance on the clinical trial selection and enrollment process
Anonymous condition-based questionnaires identify and pre-screen potentially relevant studies based on a few questions about patient diagnosis, disease stage, and treatment history

INGELHEIM, Germany & RALEIGH, N.C.--()--Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow (www.mystudywindow.com), a digital platform empowering patients, families, caregivers, and doctors to learn about Boehringer Ingelheim’s studies by offering information in an easy to access and understandable way. The collaboration brings together Carebox’ expertise in study matching based on patient eligibility criteria and Boehringer Ingelheim’s extensive scientific capabilities to pursue innovation on behalf of patients around the world.

Mohammed Ali, Global Head of Digital Development, Global Clinical Operations at Boehringer Ingelheim, says: “This initial release of MyStudyWindow represents an important step towards our vision to bring patients and physicians closer to the clinical trials environment. We plan to establish a next-generation platform empowering patients who consider to participate in or to learn about Boehringer Ingelheim studies and research. In addition, we aim to support doctors to find the information they need to consult on and pursue a well-informed treatment.”

The digital platform MyStudyWindow follows a patient-centric approach using lay friendly language, educational content and user-friendly features that provide guidance: Users can select from a range of condition-specific questionnaires to anonymously answer questions about a patient’s diagnosis, disease stage, and treatment history. MyStudyWindow instantly matches the user to potentially relevant clinical studies from the Boehringer Ingelheim portfolio, suggests nearby study site locations, and provides guidance on contacting the site for next steps. For studies that Boehringer Ingelheim would conduct in the future, patients will have the opportunity to provide feedback on their research experience to further stepping closer towards clinical trial democratization. The functions are facilitated by artificial intelligence powered automation which enables Carebox to continuously curate and structure eligibility criteria for Boehringer Ingelheim clinical trials.

“We are proud to be part of this project as the technology partner to develop and operate MyStudyWindow as a cloud-based SaaS solution”, explains Brian Weiss, CEO of Carebox Healthcare Solutions. “We are looking forward to continuing to expand the functionality and global reach of MyStudyWindow to further Boehringer Ingelheim’s commitment to patient-centric clinical research designs.”

Increasing patient and doctor awareness of clinical study opportunities and improving access is an industry challenge. Often times a lack of awareness leads to potential issues for up to 75 percent of investigators who fail to enroll the target number of participants. Furthermore, this impediment leads to as much as 90 percent of all clinical trials worldwide failing to enroll patients within the target amount of time and must extend their enrollment period.1 The parties involved in healthcare innovation increasingly recognize the role of patients and caregivers as key stakeholders in clinical research. Boehringer Ingelheim believes that the empowerment of patients and caregivers can be beneficial for study recruitment and help them to go into an informed dialog, especially those living with rare diseases.

Please click on the following link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/mystudywindow

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

Contacts

Media Contacts:
Boehringer Ingelheim
Sarah Soetbeer
Boehringer Ingelheim Corporate Center GmbH
Communications + Public Affairs
P: +49 6132 77-183874
sarah.soetbeer@boehringer-ingelheim.com

Carebox Healthcare Solutions
Brian Weiss
Carebox Healthcare Solutions, Inc.
brian.weiss@careboxhealth.com

Collaboration Requests:
Boehringer Ingelheim
Sonia Houston Pichardo
Business Lead for MyStudyWindow
sonia.houston_pichardo@boehringer-Ingelheim.com

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至 content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載APP 下載財華財經APP,把握投資先機
更多精彩内容,請點擊: 財華網(https://www.finet.hk/) 財華智庫網(https://www.finet.com.cn) 現代電視FINTV(http://www.fintv.hk)

視頻

快訊

17:36
交通銀行(03328.HK)一季度歸母淨利潤261.62億元 同比增長3.11%
17:29
工商銀行(01398.HK)一季度歸母淨利潤869.41億元 同比增長3.31
17:23
農業銀行(01288.HK)一季度歸母淨利潤751.85億元 同比增長4.52%
17:19
央行:一季度末個人住房貸款餘額36.72萬億元 同比下降3.1%
17:13
外匯局:3月中國國際收支貨物和服務貿易出口3829億美元 進口3395億美元
17:03
香港證監會對中國汽車及其附屬公司的前高層人員展開法律程序
16:57
中廣核電力(01816.HK)蒼南1號機組具備商業運營條件
16:52
中银香港(02388.HK)第一季度除稅後溢利124.93億港元 按年上升7%
16:40
新奧能源(02688.HK)一季度天然氣零售銷售量72.94億立方米 同比增長0.5%
16:24
捷佳偉創:公司布局了TOPCon、XBC等多條技術路線